NCI Outstanding Investigator Award (R35 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) invites grant applications for the Outstanding Investigator Award (R35) in any area of cancer research.

The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques. The OIA would allow an Institution to submit applications nominating established Program Directors/Principal Investigators (PDs/PIs) for the NCI OIA.

It is expected that the OIA would provide extended funding stability and encourage investigators to embark on projects of unusual potential in cancer research. The research projects should break new ground or extend previous discoveries toward new directions or applications that may lead to a breakthrough that will advance biomedical, behavioral, or clinical cancer research.

Deadlines:

  • Letter of Intent Due Date(s): 30 days prior to the application due date
  • Application Due Date(s): November 6, 2019

PAR-19-349 Expiration Date November 7, 2019

Agency Website

Eligibility Requirements

1) Applications must be submitted by Institutions who have nominated a Program Director/Principal Investigator (PD/PI) with outstanding cancer research productivity during the last 5 consecutive calendar years.

2)The Institution-nominated PD/PI must have been a PD/PI or Project Leader of a research project, excluding cores, (of a NIH-defined multi-project grant e.g., P01, P50, U54) on an eligible NCI research grant(s) continuously since September 2014. Continuous funding is defined as receiving a Notice of Award as PD/PI for an eligible NCI funded research grant in each Federal Fiscal Year beginning in FY 2014 onward. Continuous funding does not include grants in a funded or unfunded extension. Eligible NCI research grant mechanisms are defined as R01, R15, R33, R37, P01, P50, U01, U54, UM1, U19, U10, DP1, and DP2.

3) Due to the nature of this award, applicants are required to devote at least 6 person months effort to the OIA. Applicants with administrative responsibilities or other duties inconsistent with this time commitment may apply but must reduce those other commitments to accept the award.

4) PDs/PIs with effort on other grant support will be expected to provide, as part of the Just-in-Time information, a detailed explanation describing how effort on his/her other grants will be adjusted, if necessary, to permit 6 person months on the OIA.

5) PD/PIs will need to renegotiate their time and effort on other grant support, if necessary, in order to accommodate the OIA level of effort.

In addition, grantee Institutions are expected to:

1) provide clear and continuing substantial commitment to the PD/PI, for example providing at least 20% salary support for the duration of the award;

2) agree to relinquish the PD/PI's existing NCI funded single PD/PI and single project research grants to allow them to be consolidated into the OIA

To prevent a lapse in funding, a PD/PI may submit a competitive R01 application and an OIA application in parallel. Should both applications be meritorious and considered for funding, the PD/PI may be permitted to accept only one of the awards pending negotiation with IC staff.

      Amount

      $4,200,000

      Amount Description

      Awards will be for $600,000 direct costs per year, plus applicable Facilities and Administrative (F&A) costs to be determined at the time of award.

      The total project period may not exceed 7 years.      

      Funding Type

      Award
      Grant

      Eligibility

      Faculty

      Category

      Medical
      Medical - Basic Science
      Medical - Clinical Science
      Medical - Translational
      Social Sciences

      External Deadline

      November 6, 2019